Impact of [
Amino acid
Glioma
Regularized reconstruction
Tumor grade
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
27
11
2023
accepted:
02
02
2024
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
aheadofprint
Résumé
The uptake of [ We categorized 32 gliomas in 28 patients as grades 2/3 (n = 15) and 4 (n = 17) based on the WHO 2021 classification. All [ The mean SUV The BPL increased mean SUV
Identifiants
pubmed: 38466549
doi: 10.1007/s12149-024-01911-x
pii: 10.1007/s12149-024-01911-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K16747
Organisme : Japan Society for the Promotion of Science
ID : JP23K14875
Informations de copyright
© 2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–105.
pubmed: 34608945
pmcid: 8491279
doi: 10.1093/neuonc/noab200
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.
pubmed: 34185076
pmcid: 8328013
doi: 10.1093/neuonc/noab106
Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know-a minireview. Acta Neurochir (Wien). 2022;164(9):2453–64.
pubmed: 35879477
doi: 10.1007/s00701-022-05301-y
Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4): e13062.
pubmed: 35289001
pmcid: 9245936
doi: 10.1111/bpa.13062
Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med. 2011;52(10):1585–600.
pubmed: 21840931
doi: 10.2967/jnumed.110.084210
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of
pubmed: 23232505
doi: 10.1007/s00259-012-2295-5
Falk Delgado A, Falk DA. Discrimination between primary low-grade and high-grade glioma with
pubmed: 29206062
pmcid: 5965775
doi: 10.1259/bjr.20170426
Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44(7):1155–64.
pubmed: 28110346
doi: 10.1007/s00259-017-3618-3
Russo G, Stefano A, Alongi P, Comelli A, Catalfamo B, Mantarro C, et al. Feasibility on the use of radiomics features of 11[C]-MET PET/CT in central nervous system tumours: preliminary results on potential grading discrimination using a machine learning model. Curr Oncol. 2021;28(6):5318–31.
pubmed: 34940083
pmcid: 8700249
doi: 10.3390/curroncol28060444
Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al.
pubmed: 18542957
doi: 10.1007/s00259-008-0847-5
Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for
pubmed: 17763978
doi: 10.1007/s00259-007-0557-4
Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of
pubmed: 19720290
doi: 10.1016/j.nucmedbio.2009.05.005
Nakajo K, Uda T, Kawashima T, Terakawa Y, Ishibashi K, Tsuyuguchi N, et al. Diagnostic performance of [
pubmed: 33444827
doi: 10.1016/j.wneu.2021.01.012
Ahn S, Ross SG, Asma E, Miao J, Jin X, Cheng L, et al. Quantitative comparison of OSEM and penalized likelihood image reconstruction using relative difference penalties for clinical PET. Phys Med Biol. 2015;60(15):5733–51.
pubmed: 26158503
doi: 10.1088/0031-9155/60/15/5733
Murata T, Miwa K, Miyaji N, Wagatsuma K, Hasegawa T, Oda K, et al. Evaluation of spatial dependence of point spread function-based PET reconstruction using a traceable point-like
pubmed: 27783373
pmcid: 5080272
doi: 10.1186/s40658-016-0162-3
Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV. Phantom and clinical evaluation of the bayesian penalized likelihood reconstruction algorithm Q.clear on an LYSO PET/CT system. J Nucl Med. 2015;56(9):1447–52.
pubmed: 26159585
doi: 10.2967/jnumed.115.159301
Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, et al. New PET technologies - embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48(9):2711–26.
pubmed: 34081153
pmcid: 8263417
doi: 10.1007/s00259-021-05390-4
Aljared A, Alharbi AA, Huellner MW. BSREM reconstruction for improved detection of in-transit metastases with digital FDG-PET/CT in patients with malignant melanoma. Clin Nucl Med. 2018;43(5):370–1.
pubmed: 29485444
doi: 10.1097/RLU.0000000000002024
Miwa K, Wagatsuma K, Nemoto R, Masubuchi M, Kamitaka Y, Yamao T, et al. Detection of sub-centimeter lesions using digital TOF-PET/CT system combined with Bayesian penalized likelihood reconstruction algorithm. Ann Nucl Med. 2020;34(10):762–71.
pubmed: 32623569
doi: 10.1007/s12149-020-01500-8
Te Riet J, Rijnsdorp S, Roef MJ, Arends AJ. Evaluation of a Bayesian penalized likelihood reconstruction algorithm for low-count clinical
doi: 10.1186/s40658-019-0262-y
Asma E, Ahn S, Ross SG, Chen A, Manjeshwar RM. Accurate and consistent lesion quantitation with clinically acceptable penalized likelihood images. IEEE Nucl Sci Sympos Med Imaging Conf Record. 2012;2012:4062–6.
Miwa K, Yoshii T, Wagatsuma K, Nezu S, Kamitaka Y, Yamao T, et al. Impact of gamma factor in the penalty function of Bayesian penalized likelihood reconstruction (Q.Clear) to achieve high-resolution PET images. EJNMMI Phys. 2023;10(1):4.
pubmed: 36681994
pmcid: 9868206
doi: 10.1186/s40658-023-00527-w
Reynes-Llompart G, Gamez-Cenzano C, Vercher-Conejero JL, Sabate-Llobera A, Calvo-Malvar N, Marti-Climent JM. Phantom, clinical, and texture indices evaluation and optimization of a penalized-likelihood image reconstruction method (Q.Clear) on a BGO PET/CT scanner. Med Phys. 2018;45(7):3214–22.
pubmed: 29782657
doi: 10.1002/mp.12986
Teoh EJ, McGowan DR, Bradley KM, Belcher E, Black E, Gleeson FV. Novel penalised likelihood reconstruction of PET in the assessment of histologically verified small pulmonary nodules. Eur Radiol. 2016;26(2):576–84.
pubmed: 25991490
doi: 10.1007/s00330-015-3832-y
Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38(10):5394–411.
pubmed: 21992359
doi: 10.1118/1.3635220
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.
pubmed: 29173917
doi: 10.1016/j.ejmp.2017.09.124
Ogishima T, Tamura K, Kobayashi D, Inaji M, Hayashi S, Tamura R, et al. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Brain Tumor Pathol. 2017;34(1):20–7.
pubmed: 28251430
doi: 10.1007/s10014-017-0280-1
Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133–46.
pubmed: 25427834
doi: 10.1007/s00401-014-1370-3
Ebiko Y, Tamura K, Hara S, Inaji M, Tanaka Y, Nariai T, et al. T2-FLAIR mismatch sign correlates with
pubmed: 37589920
doi: 10.1007/s11060-023-04417-0
Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9(8): e105682.
pubmed: 25162396
pmcid: 4146536
doi: 10.1371/journal.pone.0105682
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540–57.
pubmed: 30519867
doi: 10.1007/s00259-018-4207-9
Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zahringer M, et al. Towards standardization of
pubmed: 28560582
pmcid: 5449315
doi: 10.1186/s13550-017-0295-y
Krokos G, Pike LC, Cook GJR, Marsden PK. Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. EJNMMI Phys. 2021;8(1):52.
pubmed: 34273020
pmcid: 8286213
doi: 10.1186/s40658-021-00400-8
Texte E, Gouel P, Thureau S, Lequesne J, Barres B, Edet-Sanson A, et al. Impact of the Bayesian penalized likelihood algorithm (Q.Clear®) in comparison with the OSEM reconstruction on low contrast PET hypoxic images. EJNMMI Phys. 2020;7(1):28.
pubmed: 32399752
pmcid: 7218037
doi: 10.1186/s40658-020-00300-3
Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA. Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther. 2019;12(2):82–8.
pubmed: 30552865
doi: 10.1016/j.hemonc.2018.11.001
Armocida D, Frati A, Salvati M, Santoro A, Pesce A. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin Neurol Neurosurg. 2020;198: 106126.
pubmed: 32861131
doi: 10.1016/j.clineuro.2020.106126
Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 2006;12(3):143–7.
pubmed: 16998593
doi: 10.1007/BF02893360
Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, et al. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget. 2015;6(30):30232–8.
pubmed: 26338964
pmcid: 4745793
doi: 10.18632/oncotarget.4920
Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol. 2012;2012: 205818.
pubmed: 22577290
pmcid: 3336213
doi: 10.1155/2012/205818
Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borros G, Martinez-Ricarte F, Cordero E, Martinez-Saez E, et al. Role of [
pubmed: 26588352
doi: 10.1016/j.clineuro.2015.10.035
Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, et al.
pubmed: 22766670
pmcid: 7966311
doi: 10.3174/ajnr.A3173
Laudicella R, Albano D, Alongi P, Argiroffi G, Bauckneht M, Baldari S, et al.
pubmed: 31514479
pmcid: 6769578
doi: 10.3390/cancers11091348
Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, et al. [
pubmed: 30046944
pmcid: 6060188
doi: 10.1186/s13550-018-0415-3
Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y. Diagnosis of brain tumors using amino acid transport PET imaging with
pubmed: 28660218
pmcid: 5482923